Last reviewed · How we verify
NCT05417971
Reduced Intensity Fludarabine and TBI Prior to Haplo-Identical Transplantation
trial testing Fludarabine in Hematologic Malignancy in 20 participants. Currently enrolling.
31 July 2026
Quick facts
| Lead sponsor | Northside Hospital, Inc. |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 20 |
| Start date | 29 August 2022 |
| Primary completion | 31 July 2026 |
| Estimated completion | 31 December 2026 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Fludarabine (FLUDARABINE) — full drug profile →
Conditions studied
- Hematologic Malignancy — all drugs for Hematologic Malignancy →
Sponsor
Northside Hospital, Inc.
Who can join
18 and older, any sex, with Hematologic Malignancy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This trial will evaluate the safety and efficacy of RIC HIDT transplant protocol following fludarabine and intermediate-dose TBI 800 cGy utilizing PBSC as the stem cell source.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05417971
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Fludarabine
Trials testing the same drug.
- NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
- NCT07509008 — Phase 1/2 Window Of Opportunity Study Of TROP2 CAR/IL-15 TGFBR2 KO NK Cells Delivered Intraperitoneally For The Manageme · Phase 1, PHASE2 · not yet recruiting
- NCT07444632 — Phase1 Basket Trial Of CAR.70-Engineered IL15-Transduced With TGFBR2 Knock Out Cord Blood-Derived NK Cells For Relapsed/ · Phase 1 · not yet recruiting
- NCT07428486 — A Phase 1 Study Of FLAG Chemotherapy In Combination With Lisaftoclax And Pelcitoclax In Patients With Relapsed/Refractor · Phase 1 · not yet recruiting
- NCT07411599 — Dual Administration Of Intraperitoneal And Intravenous TROP2-Directed CAR-NK With TGF-Beta Receptor 2 (TGFBR2) Knock Out · Phase 1, PHASE2 · not yet recruiting
Other recruiting trials for Hematologic Malignancy
Currently open trials in the same condition.
- NCT06856226 — Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing · recruiting
- NCT07511127 — Comparing the Efficacy of Different Durations of Maribavir Treatment Regimens in Allo-HSCT · Phase 3 · recruiting
- NCT07413991 — Expressive Writing Program Among Young Adults With Blood Cancer · NA · active not recruiting
- NCT06487247 — HEME Home Transfusion Program · NA · recruiting
- NCT07035938 — T-cell Developmental Status in Patients With Malignant Hematological Tumors · recruiting
Other Northside Hospital, Inc. trials
Trials by the same sponsor.
- NCT07511062 — Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated AML · Phase 1 · not yet recruiting
- NCT06828796 — Early Use of Tacrolimus in HLA-Mismatched Haploidentical Allogeneic Hematopoietic Transplantation With Post-Transplant C · Phase 2 · recruiting
- NCT05909059 — CAR T-cell Therapy in Patients With Renal Dysfunction · Phase 2 · recruiting
- NCT06337331 — Adding Venetoclax to the High-dose Chemotherapy Regimen Prior to Mismatche Allogeneic Stem Cell Transplant · Phase 2 · withdrawn
- NCT06046248 — Belumosudil and Rituximab for Primary Treatment of Chronic Graft-Versus-Host-Disease · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05417971 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Northside Hospital, Inc.
- Last refreshed: 16 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05417971.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing